Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Grace Therapeutics ( (GRCE) ) is now available.
On September 18, 2025, Grace Therapeutics announced that the U.S. Patent and Trademark Office issued a new patent for their GTx-104 drug, extending protection until 2043. This patent covers the dosing regimen for intravenous administration of nimodipine, used in the Phase 3 STRIVE-ON safety trial, and strengthens the company’s intellectual property portfolio. The STRIVE-ON trial demonstrated that GTx-104 reduced the incidence of hypotension and improved functional outcomes compared to oral nimodipine, with fewer ICU readmissions and comparable safety profiles. This development is expected to enhance the market value of GTx-104 and deliver value to stakeholders.
The most recent analyst rating on (GRCE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Grace Therapeutics stock, see the GRCE Stock Forecast page.
Spark’s Take on GRCE Stock
According to Spark, TipRanks’ AI Analyst, GRCE is a Neutral.
Grace Therapeutics is navigating a challenging financial landscape, marked by no revenue and persistent operational losses, which are somewhat mitigated by a strong equity base and absence of debt. The stock shows positive technical momentum but is at risk of being overbought. The negative P/E ratio highlights the risk associated with the company’s current financial performance and lack of earnings. Strategic management is required to improve operational viability and financial sustainability.
To see Spark’s full report on GRCE stock, click here.
More about Grace Therapeutics
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing drug candidates for rare and orphan diseases. The company leverages novel drug delivery technologies to enhance the performance of existing drugs, aiming for faster onset of action, improved efficacy, reduced side effects, and more convenient delivery. Their lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal subarachnoid hemorrhage (aSAH), a rare and life-threatening condition.
Average Trading Volume: 80,820
Technical Sentiment Signal: Hold
Current Market Cap: $42.32M
See more data about GRCE stock on TipRanks’ Stock Analysis page.